The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 3, 1998, Pages 195-203

  Berenson, James R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID;

BONE ATROPHY; BONE DESTRUCTION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE MYELOMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL TIME;

EID: 0031872826     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Alexanian RH, Dimopoulos MA. Management of multiple myeloma. Semin Hematol 1995; 32: 20-30.
2. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects of multiple myeloma cells induced by bisphosphonates. Leukemia, 1998; 12: 220-229.
3. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo. Br J Haematol 1995; 90: 721-724.
4. Belch AR, Bergsagel DE, Wilson K et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9: 1397-1402.
5. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N EngI J Med 1996; 334: 488-493.
6. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593-602.
7. Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993; 19: 79-103.
8. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854.
9. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Rec Results Cancer Res 1989; 116: 1-28.
10. Hayward JL, Carbone PP, Heuson J-C et al. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289-1294.
11. Heim ME, Clemens MR, Queisser W et al. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie 1995; 18: 439-448.
12. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478-1487.
13. Kanis JA, McCloskey EV, Taube T et al. Rationale for the use of bisphosphonates in bone metastases. Bone 1991; 12 (Suppl 1): S13-S18.
14. Kellihan MJ, Mangino PD: Pamidronate. Ann Pharmacother 1992; 26: 1262-1269.
15. Klein B, Zhang X-G, Lu Z-Y. Interleukin-6 in multiple myeloma. Blood 1995; 85: 863-872.
16. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50: 29-40.
17. Kyle RA, Jowsey J, Kelly PJ, Taves DR. Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 1975; 293: 1334-1338.
18. Laakso M, Lahtinen R, Virkkunen P, Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 1994; 87: 725-729.
19. Lahtinen R, Laakso M, Palva I et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-1052.
20. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995; 162: 248-255.
21. Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
22. Man Z, Otero AB, Rendo P et al. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990; 335: 663.
23. Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991; 12 (Suppl 1): S1-S6.
24. Mundy GR, Bertoline DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986; 13: 291-299.
25. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994; 70: 554-558.
26. Radl J, Croese JW, Zurcher C et al. Influence of treatment with APD-bisphosphonate on the bone lesions in the 5T2 multiple myeloma. Cancer 1985; 55:1030-1040.
27. Sasaki A, Boyce BF, Story B et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 3551-3557.
28. Savage AD, Belson DJ, Vescio RA et al. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 1996; 88: 105a.
29. Stashenko P, Dewhirst FE, Peros WJ et al. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987; 138: 1464-1468.
30. Thiébaud D, Leyuraz S, Von Fliedner V et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991; 27: 37-41.
31. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM et al. Palliative treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 491-198.